Navigation Links
Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
Date:4/5/2011

IPSWICH, Mass. and SAN DIEGO, April 5, 2011 /PRNewswire/ -- New England Biolabs, Inc. (NEB) and Sequenom, Inc. (NASDAQ: SQNM) jointly announce that they have signed a licensing and co-marketing agreement to commercialize research tools for epigenetics. This agreement is the result of a research collaboration between the two companies that has culminated in the development of the EpiMark™ Methylated DNA Enrichment Kit from NEB.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b)

The EpiMark Methylated DNA Enrichment Kit utilizes the innovative proprietary technology and intellectual property, methyl-CpG-immunoprecipitation (MCIp), acquired by Sequenom through an assignment of intellectual property rights from the University of Regensburg, Germany.  The MCIp technology is based on the work of Prof. Michael Rehli at the Department of Hematology and Oncology.  It is used to advance discovery and analysis of differentially methylated regions in biological samples, such as methylation differences between fetal and maternal chromosomes that can enable non-invasive prenatal diagnostics.

The EpiMark Methylated DNA Enrichment Kit incorporates the methyl-CpG binding domain of human MBD2, fused to the Fc tail of human IgG1.  When coupled to magnetic beads, this antibody-like protein enables purification of methylated CpG DNA with superior sensitivity, accuracy and speed. NEB has enabled and optimized large-scale, high purity manufacturing of the protein and developed a user-friendly kit for the research community.

NEB will also be Sequenom's first choice supplier if the technology should be utilized for prenatal diagnostic purposes in the future. Sequenom has retained all rights for diagnostic uses.

"Collaborations have always played an essential role in the development of innovative research tools at New England Biolabs," states Dr. Salvatore Russello, Associate Director of Business Development at NEB. "This collaboration has been of great value to NEB and has facilitated the development of a novel tool to drive the discovery of epigenetic markers, an exciting new area of basic and applied research."

Dr. Karsten Schmidt, VP of Business Development at Sequenom commented, "We are pleased that through a productive collaborative effort with NEB, we are able to make available to the research community a research reagent that should have broad applicability in the detection and analysis of differential DNA methylation."

The EpiMark Methylated DNA Enrichment Kit is part of a suite of EpiMark validated products for epigenetics, which was launched by New England Biolabs at the AACR 2011 Annual Meeting (Orlando, FL; April 2–6, 2011). For more information, visit www.epimark.com.

About NEB

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM(R) is a trademark of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OmniComm Systems Awarded 4 Clinical Trials from U.S. Biotechnology Company
2. Central Texas Hospital Selects eCareSoft EHR Technology
3. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
4. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. "IVD Technology" Announces Upcoming Webcast: Omics and the Development of IVDs
7. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
8. California Oncology Group Uses New Technology to Choose Best Cancer Treatment
9. Navinta LLC is Pleased to Announce US FDA Approval of Sodium Ferric Gluconate Injection in Sucrose [a generic equivalent of Ferrlecit® Injection by Sanofi Aventis] Based on Its Proprietary Technology
10. Virtual Radiologic Wins Stevie® Award for Improving Patient Care through Mobile Technology
11. U.S. Department of Energy Hails Dilon Diagnostics as a Medical Technology Pioneer and Top National Innovator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
Breaking Medicine Technology:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
Breaking Medicine News(10 mins):